Related Experiment Video
Updated: May 19, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Ventricular assist devices in acute heart failure
C Cereghetti1, C Kaiser, S Cook
1Department of Cardiology, Fribourg & Basel, University Hospital, Fribourg, Switzerland.
Minerva Cardioangiologica
|August 4, 2012
Summary
Acute heart failure and cardiogenic shock are rising, with poor prognoses. Percutaneous left ventricular assistance devices (LVADs) offer a promising treatment option when initial therapies fail.
Area of Science:
- Cardiology
- Medical Devices
- Critical Care Medicine
Background:
- Acute heart failure incidence is increasing in Western countries, leading to higher mortality rates.
- Cardiogenic shock, a severe form of acute heart failure, presents a dismal prognosis.
- Conventional treatments for cardiogenic shock may be insufficient, necessitating advanced interventions.
Purpose of the Study:
- To review the technical aspects of percutaneous left ventricular assistance devices (LVADs).
- To present clinical data on available percutaneous LVADs in Europe.
- To evaluate LVADs as a treatment for overt cardiogenic shock.
Main Methods:
- Review of technical characteristics of percutaneous LVADs.
- Analysis of clinical data for LVADs used in cardiogenic shock treatment.
- Focus on devices available in the European market.
Main Results:
- Technical advancements enable rapid, percutaneous implantation of LVADs.
- LVADs represent a viable option when standard therapies are overcome.
- Data on specific percutaneous LVADs available in Europe are discussed.
Conclusions:
- Percutaneous LVADs are increasingly important for managing cardiogenic shock.
- These devices offer a less invasive approach compared to traditional mechanical support.
- Further evaluation of LVADs is crucial for optimizing cardiogenic shock treatment.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:25Hemodialysis I: Introduction
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...